Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The concept of **urinary tract flora**—more accurately called the *urinary tract microbiome*—refers to the diverse community of **microorganisms** (predominantly bacteria) that inhabit the urinary tract, including the bladder and urethra, in both health and disease. Once thought to be sterile, the urinary tract contains resident microbial populations distinct from the gut or vaginal microbiomes. The core genera frequently include **Lactobacillus, Streptococcus, Corynebacterium, Gardnerella, Prevotella, and Escherichia**, among others. The composition varies widely by sex, hormonal status, age, and health, with Lactobacillus being dominant in healthy females of reproductive age. Dysbiosis—an imbalance in this microbial community—has been implicated in urinary tract infections, kidney stones, incontinence, and possibly cancer, making its composition a key factor in urinary health. While the *urinary tract microbiome* is not a single therapeutic target like a receptor or enzyme, emerging therapies include modulation with antibiotics, probiotics, or fecal microbiota transplantation to restore a balanced microbiome and combat recurrent infection or other pathology[1][2][3][4][6][7]. Note: - The term "Urinary tract flora" does not refer to a discrete molecular target, but rather to a **complex ecological community**. Thus, it is not considered a "therapeutic target" in the conventional sense of receptor, enzyme, or gene, and **the query as stated is incorrect for target curation purposes**[6][4]. - The proper scientific term is "Urinary tract microbiome" or "urobiome." - No canonical abbreviation is established; “UT microbiome” or “urobiome” are sometimes informally used. - The urinary microbiome is increasingly seen as a modifiable factor affecting urologic disease, but it cannot be targeted like a single protein or enzyme. - For structured databases of drug targets, this should be classified as “not a valid molecular target.”
Antibiotic-induced depletion or alteration of microbial communities; Probiotic colonization to restore or enhance beneficial taxa; FMT to restore microbial diversity and resist uropathogen colonization
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Urinary tract microbiome.